Accès gratuit
Med Sci (Paris)
Volume 28, Numéro 6-7, Juin–Juillet 2012
Page(s) 605 - 611
Section M/S Revues
Publié en ligne 16 juillet 2012
  1. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007 ; 178 : 2827–2834. [PubMed]
  2. Parrish-Novak J, Dillon S, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000 ; 408 : 57–63. [CrossRef] [PubMed]
  3. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008 ; 26 : 57–79. [CrossRef] [PubMed]
  4. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003 ; 102 : 4090–4098. [CrossRef] [PubMed]
  5. Caruso R, Fina D, Peluso I, et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 2007 ; 178 : 5957–5965. [PubMed]
  6. Distler JH, Jungel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005 ; 52 : 856–864. [CrossRef] [PubMed]
  7. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004 ; 173 : 657–665. [PubMed]
  8. Ozaki K, Kikly K, Michalovich D, et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 2000 ; 97 : 11439–11444. [CrossRef]
  9. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002 ; 72 : 856–863. [PubMed]
  10. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008 ; 20 : 295–301. [CrossRef] [PubMed]
  11. Battegay M, Moskophidis D, Rahemtulla A, et al. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 1994 ; 68 : 4700–4704. [PubMed]
  12. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994 ; 68 : 8056–8063. [PubMed]
  13. Ou R, Zhou S, Huang L, Moskophidis D. Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J Virol 2001 ; 75 : 8407–8423. [CrossRef] [PubMed]
  14. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009 ; 324 : 1569–1572. [CrossRef] [PubMed]
  15. Frohlich A, Kisielow J, Schmitz I, et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009 ; 324 : 1576–1580. [CrossRef] [PubMed]
  16. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009 ; 324 : 1572–1576. [CrossRef] [PubMed]
  17. Barker BR, Gladstone MN, Gillard GO, et al. Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. Eur J Immunol 2010 ; 40 : 3085–3096. [CrossRef] [PubMed]
  18. Publicover J, Goodsell A, Nishimura S, et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011 ; 121 : 1154–1162. [CrossRef] [PubMed]
  19. Pallikkuth S, Pilakka Kanthikeel S, Silva SY, et al. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol 2011 ; 186 : 6173–6181. [CrossRef] [PubMed]
  20. Rankin AL, MacLeod H, Keegan S, et al. IL-21 receptor is critical for the development of memory B cell responses. J Immunol 2011 ; 186 : 667–674. [CrossRef] [PubMed]
  21. Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010 ; 207 : 155–171. [CrossRef] [PubMed]
  22. Iannello A, Boulassel MR, Samarani S, et al. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol 2010 ; 184 : 114–126. [CrossRef] [PubMed]
  23. Iannello A, Tremblay C, Routy J, et al. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: Correlation with CD4+ T cell counts. Viral Immunol 2008 ; 21 : 385–388. [CrossRef] [PubMed]
  24. Chevalier MF, Julg B, Pyo A, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 2011 ; 85 : 733–741. [CrossRef] [PubMed]
  25. Yue FY, Lo C, Sakhdari A, et al. HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol 2010 ; 185 : 498–506. [CrossRef] [PubMed]
  26. Williams LD, Bansal A, Sabbaj S, et al. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J Virol 2011 ; 85 : 2316–2324. [CrossRef] [PubMed]
  27. Iannello A, Boulassel MR, Samarani S, et al. IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication. J Leukoc Biol 2010 ; 87 : 857–867. [CrossRef] [PubMed]
  28. Parmigiani A, Pallin MF, Schmidtmayerova H, et al. Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells. Hum Immunol 2011 ; 72 : 115–123. [CrossRef] [PubMed]
  29. Abrams D, Lévy Y, Losso M, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009 ; 361 : 1548–1559. [CrossRef] [PubMed]
  30. Pallikkuth S, Rogers K, Villinger F, et al. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011 ; 29 : 9229–9238. [CrossRef] [PubMed]
  31. Rodrigues L, Nandakumar S, Bonorino C, et al. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response. Mol Immunol 2009 ; 46 : 1494–1504. [CrossRef] [PubMed]
  32. Cui FD, Asada H, Jin ML, et al. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice. Gene Ther 2005 ; 12 : 160–168. [CrossRef] [PubMed]
  33. Hu K, Dou J, Yu F, et al. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 2011 ; 29 : 1455–1462. [CrossRef] [PubMed]
  34. Van Leeuwen EM, Gamadia LE, Baars PA, et al. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J Immunol 2002 ; 169 : 5838–5843. [PubMed]
  35. Van Leeuwen EM, van Buul JD, Remmerswaal EB, et al. Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation. Int Immunol 2005 ; 17 : 713–719. [CrossRef] [PubMed]
  36. Bolesta E, Kowalczyk A, Wierzbicki A, et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 2006 ; 177 : 177–191. [PubMed]
  37. Leung-Theung-Long S, Guerder S. Les cellules Th17 : une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008 ; 24 : 972–976. [CrossRef] [EDP Sciences] [PubMed]
  38. Lambotte O. Les patients HIV controllers. Med Sci (Paris) 2012 ; 28 : 172–178. [CrossRef] [EDP Sciences] [PubMed]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.